---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-004387"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:15:16.634199+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Annexon outlines 2024 clinical milestones: Phase 3 GBS data H1 2024, GA trial start mid-2024

## Summary
- Phase 3 pivotal data for ANX005 in Guillain-Barré syndrome on track for first half of 2024; potential first approved treatment in U.S.
- Global pivotal program for ANX007 in geographic atrophy (ARCHER II) to initiate mid-2024 with vision preservation as primary endpoint
- Proof-of-concept study for oral C1s inhibitor ANX1502 in cold agglutinin disease to start first half of 2024
- Completed $125 million financing extends operating runway into second quarter 2026
- ANX007 received PRIME designation in EU; to launch head-to-head ARROW trial vs. SYFOVRE in late 2024

## SEC filing metadata
- accession: 0001193125-24-004387
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312524004387/0001193125-24-004387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312524004387/d609684d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-004387
- JSON: https://secwatch.observer/filing/0001193125-24-004387.json
- Plain text: https://secwatch.observer/filing/0001193125-24-004387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.